Institution
University of South Australia
Education•Adelaide, South Australia, Australia•
About: University of South Australia is a education organization based out in Adelaide, South Australia, Australia. It is known for research contribution in the topics: Population & Context (language use). The organization has 10086 authors who have published 32587 publications receiving 913683 citations. The organization is also known as: The University of South Australia & UniSA.
Papers published on a yearly basis
Papers
More filters
••
Columbia University Medical Center1, Regenstrief Institute2, Stanford University3, AstraZeneca4, University of Hong Kong5, University of California, Los Angeles6, Ajou University7, Erasmus University Medical Center8, University of South Australia9, Uppsala Monitoring Centre10, Taipei Medical University11, Janssen Pharmaceutica12, Columbia University13
TL;DR: Observational Health Data Sciences and Informatics has built on learnings from the Observational Medical Outcomes Partnership to turn methods research and insights into a suite of applications and exploration tools that move the field closer to the ultimate goal of generating evidence about all aspects of healthcare.
Abstract: The vision of creating accessible, reliable clinical evidence by accessing the clincial experience of hundreds of millions of patients across the globe is a reality. Observational Health Data Sciences and Informatics (OHDSI) has built on learnings from the Observational Medical Outcomes Partnership to turn methods research and insights into a suite of applications and exploration tools that move the field closer to the ultimate goal of generating evidence about all aspects of healthcare to serve the needs of patients, clinicians and all other decision-makers around the world.
716 citations
••
TL;DR: Unpublished clinical data on nanoparticle penetration and previously published reports support the hypothesis that nanoparticles >10nm in diameter are unlikely to penetrate through the stratum corneum into viable human skin but will accumulate in the hair follicle openings, especially after massage.
707 citations
••
TL;DR: The thermoelectric properties of various poly(3,4-ethylenedioxythiophene) samples are measured, and a marked increase in the Seebeck coefficient is observed when the electrical conductivity is enhanced through molecular organization, which initiates the transition from a Fermi glass to a semi-metal.
Abstract: Polymers are lightweight, flexible, solution-processable materials that are promising for low-cost printed electronics as well as for mass-produced and large-area applications. Previous studies dem ...
705 citations
••
Commonwealth Scientific and Industrial Research Organisation1, Deakin University2, South China Agricultural University3, College of Horticulture4, University of South Australia5, University of Adelaide6, Beijing Normal University7, Arizona State University8, Chinese Academy of Sciences9, Inner Mongolia University10, Inner Mongolia Agricultural University11
TL;DR: It is overwhelmingly that the interventions improved the sustainability of China’s rural land systems, but the impacts are nuanced and adverse outcomes have occurred.
Abstract: China has responded to a national land-system sustainability emergency via an integrated portfolio of large-scale programmes. Here we review 16 sustainability programmes, which invested US$378.5 billion (in 2015 US$), covered 623.9 million hectares of land and involved over 500 million people, mostly since 1998. We find overwhelmingly that the interventions improved the sustainability of China’s rural land systems, but the impacts are nuanced and adverse outcomes have occurred. We identify some key characteristics of programme success, potential risks to their durability, and future research needs. We suggest directions for China and other nations as they progress towards the Sustainable Development Goals of the United Nations’ Agenda 2030.
702 citations
••
TL;DR: A high proportion of patients achieved an intracranial response with the combination of nivolumab alone or in combination with ipilimumab, which should be considered as a first-line therapy for patients with asymptomatic untreated brain metastases.
Abstract: Summary Background Nivolumab monotherapy and combination nivolumab plus ipilimumab increase proportions of patients achieving a response and survival versus ipilimumab in patients with metastatic melanoma; however, efficacy in active brain metastases is unknown. We aimed to establish the efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with active melanoma brain metastases. Methods This multicentre open-label randomised phase 2 trial was done at four sites in Australia, in three cohorts of immunotherapy-naive patients aged 18 years or older with melanoma brain metastases. Patients with asymptomatic brain metastases with no previous local brain therapy were randomly assigned using the biased coin minimisation method, stratified by site, in a 30:24 ratio (after a safety run-in of six patients) to cohort A (nivolumab plus ipilimumab) or cohort B (nivolumab). Patients with brain metastases in whom local therapy had failed, or who had neurological symptoms, or leptomeningeal disease were enrolled in non-randomised cohort C (nivolumab). Patients in cohort A received intravenous nivolumab 1 mg/kg combined with ipilimumab 3 mg/kg every 3 weeks for four doses, then nivolumab 3 mg/kg every 2 weeks; patients in cohort B or cohort C received intravenous nivolumab 3 mg/kg every 2 weeks. The primary endpoint was intracranial response from week 12. Primary and safety analyses were done on an intention-to-treat basis in all patients who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, number NCT02374242, and is ongoing for the final survival analysis. Findings Between Nov 4, 2014, and April 21, 2017, 79 patients were enrolled; 36 in cohort A, 27 in cohort B, and 16 in cohort C. One patient in cohort A and two in cohort B were found to be ineligible and excluded from the study before receiving the study drug. At the data cutoff (Aug 28, 2017), with a median follow up of 17 months (IQR 8–25), intracranial responses were achieved by 16 (46%; 95% CI 29–63) of 35 patients in cohort A, five (20%; 7–41) of 25 in cohort B, and one (6%; 0–30) of 16 in cohort C. Intracranial complete responses occurred in six (17%) patients in cohort A, three (12%) in cohort B, and none in cohort C. Treatment-related adverse events occurred in 34 (97%) of 35 patients in cohort A, 17 (68%) of 25 in cohort B, and eight (50%) of 16 in cohort C. Grade 3 or 4 treatment-related adverse events occurred in 19 (54%) patients in cohort A, four (16%) in cohort B, and two (13%) in cohort C. No treatment-related deaths occurred. Interpretation Nivolumab combined with ipilimumab and nivolumab monotherapy are active in melanoma brain metastases. A high proportion of patients achieved an intracranial response with the combination. Thus, nivolumab combined with ipilimumab should be considered as a first-line therapy for patients with asymptomatic untreated brain metastases. Funding Melanoma Institute Australia and Bristol-Myers Squibb.
687 citations
Authors
Showing all 10298 results
Name | H-index | Papers | Citations |
---|---|---|---|
Andrew P. McMahon | 162 | 415 | 90650 |
Timothy P. Hughes | 145 | 831 | 91357 |
Jeremy K. Nicholson | 141 | 773 | 80275 |
Peng Shi | 137 | 1371 | 65195 |
Daniel Thomas | 134 | 846 | 84224 |
Jian Li | 133 | 2863 | 87131 |
Matthew Jones | 125 | 1161 | 96909 |
Ulrich S. Schubert | 122 | 2229 | 85604 |
Elaine Holmes | 119 | 560 | 58975 |
Arne Astrup | 114 | 866 | 68877 |
Richard Gray | 109 | 808 | 78580 |
John B. Furness | 103 | 597 | 37668 |
Thomas J. Jentsch | 101 | 238 | 32810 |
Ben W.J. Mol | 101 | 1485 | 47733 |
John C. Lindon | 99 | 488 | 44063 |